vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

ESCALADE INC is the larger business by last-quarter revenue ($62.6M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). ESCALADE INC runs the higher net margin — 5.9% vs -83.0%, a 88.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -2.2%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 4.5%).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

ESCA vs RYTM — Head-to-Head

Bigger by revenue
ESCA
ESCA
1.1× larger
ESCA
$62.6M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+39.0% gap
RYTM
36.9%
-2.2%
ESCA
Higher net margin
ESCA
ESCA
88.9% more per $
ESCA
5.9%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESCA
ESCA
RYTM
RYTM
Revenue
$62.6M
$57.3M
Net Profit
$3.7M
$-47.5M
Gross Margin
27.7%
91.6%
Operating Margin
8.2%
-82.2%
Net Margin
5.9%
-83.0%
Revenue YoY
-2.2%
36.9%
Net Profit YoY
37.1%
-9.6%
EPS (diluted)
$0.27
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
RYTM
RYTM
Q4 25
$62.6M
$57.3M
Q3 25
$67.8M
$51.3M
Q2 25
$54.3M
$48.5M
Q1 25
$55.5M
$32.7M
Q4 24
$63.9M
$41.8M
Q3 24
$67.7M
$33.3M
Q2 24
$62.5M
$29.1M
Q1 24
$57.3M
$26.0M
Net Profit
ESCA
ESCA
RYTM
RYTM
Q4 25
$3.7M
$-47.5M
Q3 25
$5.6M
$-52.9M
Q2 25
$1.8M
$-46.6M
Q1 25
$2.6M
$-49.5M
Q4 24
$2.7M
$-43.3M
Q3 24
$5.7M
$-43.6M
Q2 24
$2.8M
$-32.3M
Q1 24
$1.8M
$-141.4M
Gross Margin
ESCA
ESCA
RYTM
RYTM
Q4 25
27.7%
91.6%
Q3 25
28.1%
89.3%
Q2 25
24.7%
88.6%
Q1 25
26.7%
88.8%
Q4 24
24.9%
90.9%
Q3 24
24.8%
88.5%
Q2 24
24.2%
89.9%
Q1 24
25.0%
89.2%
Operating Margin
ESCA
ESCA
RYTM
RYTM
Q4 25
8.2%
-82.2%
Q3 25
10.8%
-102.6%
Q2 25
4.8%
-93.4%
Q1 25
6.6%
-143.7%
Q4 24
7.1%
-98.6%
Q3 24
11.8%
-132.0%
Q2 24
7.1%
-139.2%
Q1 24
5.3%
-538.7%
Net Margin
ESCA
ESCA
RYTM
RYTM
Q4 25
5.9%
-83.0%
Q3 25
8.2%
-103.1%
Q2 25
3.4%
-96.1%
Q1 25
4.7%
-151.4%
Q4 24
4.2%
-103.6%
Q3 24
8.4%
-131.2%
Q2 24
4.5%
-110.9%
Q1 24
3.1%
-544.4%
EPS (diluted)
ESCA
ESCA
RYTM
RYTM
Q4 25
$0.27
$-0.73
Q3 25
$0.40
$-0.82
Q2 25
$0.13
$-0.75
Q1 25
$0.19
$-0.81
Q4 24
$0.20
$-0.71
Q3 24
$0.40
$-0.73
Q2 24
$0.20
$-0.55
Q1 24
$0.13
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$388.9M
Total DebtLower is stronger
$18.5M
Stockholders' EquityBook value
$173.2M
$139.1M
Total Assets
$222.1M
$480.2M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
RYTM
RYTM
Q4 25
$388.9M
Q3 25
$416.1M
Q2 25
$291.0M
Q1 25
$314.5M
Q4 24
$320.6M
Q3 24
$298.4M
Q2 24
$319.1M
Q1 24
$201.2M
Total Debt
ESCA
ESCA
RYTM
RYTM
Q4 25
$18.5M
Q3 25
Q2 25
Q1 25
Q4 24
$25.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESCA
ESCA
RYTM
RYTM
Q4 25
$173.2M
$139.1M
Q3 25
$172.3M
$148.8M
Q2 25
$168.3M
$-11.9M
Q1 25
$168.8M
$18.9M
Q4 24
$169.0M
$21.7M
Q3 24
$170.1M
$11.2M
Q2 24
$166.0M
$39.3M
Q1 24
$164.7M
$61.6M
Total Assets
ESCA
ESCA
RYTM
RYTM
Q4 25
$222.1M
$480.2M
Q3 25
$232.5M
$506.9M
Q2 25
$218.3M
$372.7M
Q1 25
$222.1M
$386.7M
Q4 24
$226.3M
$392.3M
Q3 24
$244.9M
$363.6M
Q2 24
$243.1M
$381.8M
Q1 24
$256.3M
$258.7M
Debt / Equity
ESCA
ESCA
RYTM
RYTM
Q4 25
0.11×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
RYTM
RYTM
Operating Cash FlowLast quarter
$14.9M
$-25.4M
Free Cash FlowOCF − Capex
$13.7M
FCF MarginFCF / Revenue
21.8%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
4.02×
TTM Free Cash FlowTrailing 4 quarters
$28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
RYTM
RYTM
Q4 25
$14.9M
$-25.4M
Q3 25
$-965.0K
$-26.6M
Q2 25
$13.3M
$-23.3M
Q1 25
$3.8M
$-40.4M
Q4 24
$12.3M
$-18.8M
Q3 24
$10.5M
$-25.2M
Q2 24
$13.3M
$-29.1M
Q1 24
$7.0K
$-40.7M
Free Cash Flow
ESCA
ESCA
RYTM
RYTM
Q4 25
$13.7M
Q3 25
$-1.3M
Q2 25
$12.9M
Q1 25
$3.2M
Q4 24
$11.7M
Q3 24
$10.2M
Q2 24
$12.5M
Q1 24
$-350.0K
FCF Margin
ESCA
ESCA
RYTM
RYTM
Q4 25
21.8%
Q3 25
-1.9%
Q2 25
23.7%
Q1 25
5.9%
Q4 24
18.4%
Q3 24
15.0%
Q2 24
20.0%
Q1 24
-0.6%
Capex Intensity
ESCA
ESCA
RYTM
RYTM
Q4 25
2.0%
Q3 25
0.4%
Q2 25
0.8%
Q1 25
1.0%
Q4 24
0.9%
Q3 24
0.5%
Q2 24
1.3%
Q1 24
0.6%
Cash Conversion
ESCA
ESCA
RYTM
RYTM
Q4 25
4.02×
Q3 25
-0.17×
Q2 25
7.28×
Q1 25
1.45×
Q4 24
4.55×
Q3 24
1.85×
Q2 24
4.67×
Q1 24
0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons